

Supplementary Figure 1. Forest plots for the assessment of OKS score between the

radiofrequency group and control group. At (a) 1-2 weeks, (b) 4 weeks, and (c) 12

weeks. OKS, Oxford knee score; SD, standard deviation; CI, confidence interval.

Α

3.41 3.87	1.65 1.67 1.7	<u>Total</u> 17 27 24	Mean 7.26 4.72	1.76 1.64	Total 18 30		IV. Fixed, 95% CI Ye -3.91 [-5.04, -2.78] 20	11
3.41 3.87	1.67 1.7	27	4.72	1.64				
3.87	1.7				30	10.00/		
		24	4 65			10.8%	-1.31 [-2.17, -0.45] 20	12
3.26			4.00	1.38	24	10.4%	-0.78 [-1.66, 0.10] 20	14
	1.39	31	4.71	1.63	31	14.1%	-1.45 [-2.20, -0.70] 20	15
2.1	1.4	22	3.6	1.6	20	9.6%	-1.50 [-2.41, -0.59] 20	16
2.47	0.92	45	3.94	1.37	47	35.5%	-1.47 [-1.95, -0.99] 20	16
3	2.3	67	3.9	2.2	69	14.0%	-0.90 [-1.66, -0.14] 20	18
2.5	1.7	15	4.4	2.3	14	3.7%	-1.90 [-3.38, -0.42] 20	19
4.62	2.44	8	7	1.8	8	1.8%	-2.38 [-4.48, -0.28] 20	21
		239			243	100.0%	-1.33 [-1.62, -1.05]	•
df = 7 ((P = 0.	68); l² :	= 0%					
	,	· ·						-4 -2 0 2 4 Favours [Radiofrequency] Favours [Control]
2	.47 3 2.5 .62	.47 0.92 3 2.3 2.5 1.7 .62 2.44	.47 0.92 45 3 2.3 67 2.5 1.7 15 .62 2.44 8 239	.47 0.92 45 3.94 3 2.3 67 3.9 2.5 1.7 15 4.4 .62 2.44 8 7 239 off = 7 (P = 0.68); I ² = 0%	.47 0.92 45 3.94 1.37 3 2.3 67 3.9 2.2 2.5 1.7 15 4.4 2.3 .62 2.44 8 7 1.8 239 df = 7 (P = 0.68); l ² = 0%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$.47 0.92 45 3.94 1.37 47 35.5% -1.47 [1.95, -0.99] 20 3 2.3 67 3.9 2.2 69 14.0% -0.90 [-1.66, -0.14] 20 2.5 1.7 15 4.4 2.3 14 3.7% -1.90 [-3.38, -0.42] 20 .62 2.44 8 7 1.8 8 1.8% -2.38 [-4.48, -0.28] 20 239 243 100.0% -1.33 [-1.62, -1.05] af F (P = 0.68); I ² = 0%

Supplementary Figure 2. Sensitivity analysis for the assessment of pain scores at 4

weeks after treatment. SD, standard deviation; CI, confidence interval.

Outcomes	No. of	WMD	Z-value	P	Heterogeneity	
Outcomes	trials	(95% CI)			l²(%)	Р
RF mode						
RFA	3	-2.17 [-3.61, -0.73]	2.95	0.003	87	0.005
Others	6	-1.31 [-1.64, -0.99]	7.88	< 0.001	0	0.45
Location						
Asia	6	-1.66 [-2.32, -1.01]	5.00	< 0.001	75	0.001
Others	3	-1.37 [-2.22, -0.52]	3.16	0.002	25	0.26
Site of radiofrequency						
Genicular nerve	4	-1.83 [-2.93, -0.72]	3.24	0.001	85	<0.00
Intra-articular	5	-1.41 [-1.77, -1.05]	7.62	< 0.001	0	0.50
Diagnosed nerve block						
Yes	3	-2.37 [-4.53, -0.21]	2.15	0.03	90	<0.00
No	6	-1.38 [-1.69, -1.07]	8.78	< 0.001	0	0.77
Sex ratio (female/male)						
< 2	5	-1.27 [-1.67, -0.87]	6.24	< 0.001	12	0.34
≥2	2	-2.68 [-5.04, -0.32]	2.23	0.03	91	0.001
BMI						
< 30	3	-2.55 [-4.34, 0.77]	2.81	0.005	87	<0.001
≥ 30	2	-1.19 [-2.08, -0.30]	2.62	0.009	28	0.24

Supplementary Table 1. Subgroup Analysis of the WMD of pain scores between two groups at 4 weeks after treatment

WMD, weighted mean difference; RF, radiofrequency; RFA, radiofrequency ablation; BMI, body mass index;

Outcomes	No. of	WMD	Z-value	P -	Heterogeneity	
	trials	(95% CI)	Z-value	Г	I ² (%)	Р
RF mode						
RFA	6	-2.26 [-2.89, -1.63]	7.02	< 0.001	88	< 0.00
Others	5	-1.12 [-2.21, -0.04]	2.03	0.04	76	0.002
Location						
Asia	8	-1.81 [-2.49, -1.14]	5.29	< 0.001	91	< 0.001
Others	3	-2.08 [-2.86, -1.30]	5.25	< 0.001	11	0.33
Site of radiofrequency						
Genicular nerve	6	-2.32 [-2.95, -1.68]	7.16	< 0.001	88	< 0.00
Intra-articular	5	-1.04 [-1.98, -0.11]	2.19	0.03	70	0.009
Diagnosed nerve block						
Yes	3	-2.65 [-3.57, -1.73]	5.65	< 0.001	37	0.20
No	8	-1.58 [-2.26, -0.90]	4.52	< 0.001	91	< 0.00
Sex ratio (female/male)						
< 2	5	-1.61 [-2.57, -0.65]	3.28	0.001	84	< 0.00
≥2	4	-2.38 [-3.53, -1.23]	4.04	< 0.001	90	< 0.00
BMI						
< 30	2	-2.79 [-4.73, -0.84]	2.81	0.005	54	0.14
≥ 30	3	-2.41 [-2.72, 2.11]	15.46	< 0.001	17	0.30

Supplementary Table 2. Subgroup Analysis of the WMD of pain scores between two groups at 12 weeks after treatment

WMD, weighted mean difference; RF, radiofrequency; RFA, radiofrequency ablation; BMI, body mass index;